- Home
- VTYX vs GRX Comparison
VTYX vs GRX Comparison
Compare VTYX & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- GRX
- Stock Information
- Founded
- VTYX 2018
- GRX 2007
- Country
- VTYX United States
- GRX United States
- Employees
- VTYX N/A
- GRX N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- GRX Finance/Investors Services
- Sector
- VTYX Health Care
- GRX Finance
- Exchange
- VTYX Nasdaq
- GRX Nasdaq
- Market Cap
- VTYX 154.9M
- GRX 145.5M
- IPO Year
- VTYX 2021
- GRX N/A
- Fundamental
- Price
- VTYX $2.30
- GRX $9.43
- Analyst Decision
- VTYX Buy
- GRX
- Analyst Count
- VTYX 2
- GRX 0
- Target Price
- VTYX $9.00
- GRX N/A
- AVG Volume (30 Days)
- VTYX 441.6K
- GRX 39.7K
- Earning Date
- VTYX 11-06-2025
- GRX 01-01-0001
- Dividend Yield
- VTYX N/A
- GRX 5.98%
- EPS Growth
- VTYX N/A
- GRX N/A
- EPS
- VTYX N/A
- GRX 0.26
- Revenue
- VTYX N/A
- GRX N/A
- Revenue This Year
- VTYX N/A
- GRX N/A
- Revenue Next Year
- VTYX N/A
- GRX N/A
- P/E Ratio
- VTYX N/A
- GRX $38.50
- Revenue Growth
- VTYX N/A
- GRX N/A
- 52 Week Low
- VTYX $0.78
- GRX $7.73
- 52 Week High
- VTYX $3.39
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- VTYX 39.52
- GRX 51.96
- Support Level
- VTYX $2.31
- GRX $9.33
- Resistance Level
- VTYX $2.54
- GRX $9.56
- Average True Range (ATR)
- VTYX 0.14
- GRX 0.09
- MACD
- VTYX -0.02
- GRX -0.01
- Stochastic Oscillator
- VTYX 0.00
- GRX 33.93
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.